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Treatment of cardiovascular disease (CVD) 
risk factors has tradi tionally been based on the 
presence or absence of a single CVD risk factor, 
such as hypertension, hyperlipidaemia or diabetes, 
without considering the continuous relationship 
between blood pressure (BP), blood glucose, blood cholesterol and 
cardiovascular risk.[1] While this approach appears straightforward, 
it may result in committing some individuals with only a small 
cardiovascular risk to years of unnecessary treatment or, conversely, 
neglecting to treat individuals with an overall higher risk.[1,2] This is 
because a combination of several slightly elevated risk factors may 
result in a much higher total risk than a single, more strikingly raised 
factor.[3,4]
Moreover, single risk factor approaches are neither cost-effective 
nor affordable for poorer individuals and in developing regions 
with limited resources.[2] Given the enormous burden of CVD 
and the high costs of management, it is therefore essential to 
prioritise cost-effective approaches that target high-risk individuals. 
Adoption of the multifactorial CVD risk assessment approach to 
identify high-risk individuals who need interventions is widely 
advocated, with the initiation of therapy based on the predicted 
absolute cardiovascular risk of the individual.[1] The total CVD risk 
assessment approach is particularly recommended as a cost-effective 
strategy in developing regions with scarce resources. Effective CVD 
prevention therefore warrants a paradigm shift from the treatment 
of single risk factors in isolation, to the management of total CVD 
risk with an improvement in the profile of all risk factors that will 
lead to the development of CVD.
Several computerised methods for estimating total cardiovascular 
risk have been developed. The first, best known and most frequently 
used risk estimation system was developed by the Framingham Heart 
Study researchers in the USA.[3,4] This score has been validated across 
different populations, modified for use in several countries and 
recommended by numerous international guideline committees for 
CVD prevention.
In South Africa (SA), the South African Heart Association and 
the Lipid and Atherosclerosis Society of Southern Africa,[5] as 
well as the Southern African Hypertension Society in conjunction 
with the National Department of Health (DoH),[6] have adopted a 
cardiovascular risk stratification approach for the management of 
CVD risk factors. Given the lack of prospective data in the African 
setting and the absence of locally validated total CVD risk assessment 
tools, and in view of the fact that the Framingham risk scores have 
been validated in white and black populations and are transportable 
to other culturally diverse populations, this approach has been 
considered appropriate for local use.[5]
Objectives. To establish the prevalence and determinants of the 10-year risk of a cardiovascular disease (CVD) event in 25 - 74-year-old 
black Africans in Cape Town, South Africa, using Framingham laboratory- and non-laboratory-based and National Health and Nutrition 
Examination Survey (NHANES) I non-laboratory-based equations.
Methods.  CVD risk factors were determined by questionnaires, clinical measurements and biochemical analyses. Survey logistic regression 
analyses assessed the sociodemographic determinants of CVD risk ≥20%.
Results. There were 1 025 participants, 369 men and 656 women. Mean 10-year risk for a CVD event by Framingham laboratory- and 
non-laboratory-based and NHANES I non-laboratory-based equations for men was 9.0% (95% confidence interval 7.7 - 10.3), 11.1% 
(9.6 - 12.6) and 9.0% (7.6 - 10.3), and for women 5.4% (4.7 - 6.1), 6.8% (5.9 - 7.7) and 8.7% (7.6 - 9.8). Correlations between laboratory- and 
non-laboratory-based scores were high (0.915 - 0.963). The prevalence of laboratory-based CVD risk ≥20% was 13.0% in men and 6.1% in 
women. In the logistic model for men, ≤7 years of education (odds ratio 3.09; 95% CI 1.67 - 5.71) and being unemployed (3.44; 1.21 - 9.81) 
compared with employed were associated with laboratory-based high risk. In women, high risk was associated with ≤7 years of education 
(4.20; 1.96 - 9.01), living in formal v. informal housing (2.74; 1.24 - 6.06) and being poor (middle v. lowest tertile 0.29; 0.13 - 0.66). In 
the Framingham non-laboratory-based logistic models there were no changes in the direction or significance of the variables except for 
housing, which was no longer significant in women.
Conclusions. Comparability of laboratory- and non-laboratory-based CVD risk estimates illustrates the utility of the latter in resource-
constrained settings.
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Most scoring systems require expensive laboratory tests; however, 
recent advances include the development of models that use simple 
office-based predictors easily obtained in primary care and do not 
require laboratory testing. The body mass index (BMI) has replaced 
total cholesterol (TC) and high-density lipoprotein (HDL) cholesterol 
in these models. Considering the increasing burden of CVD and the 
need for cost-effective use of limited resources in the developing 
world, the introduction of non-laboratory-based tools in this milieu 
is highly relevant. The use of non-laboratory-based total CVD risk 
assessment has the potential to improve worldwide utility of the risk 
scores and enhance targeted CVD prevention efforts,[3,4] particularly 
in resource-constrained settings such as SA, where widespread 
laboratory availability is problematic and not economically feasible.
This study aimed to determine the 10-year risk of developing a CVD 
event in the black population of Cape Town using the Framingham 
laboratory- and non-laboratory-based equations. Additionally, the 
non-laboratory-based score developed using the National Health and 
Nutrition Examination Survey (NHANES) I population data in the 
USA was used to calculate total CVD risk. This equation was found 
to be highly correlated with commonly used laboratory scores in SA 
populations.[7] The sociodemographic determinants associated with 
high-risk scores (≥20%) were also ascertained.
Methods
Study population and sampling procedure
A sample of 25 - 74-year-old men and women in the predominantly 
black residential areas of Langa, Guguletu, Crossroads, Nyanga 
and Khayelitsha in Cape Town participated in this cross-sectional 
study in 2008/09. The sampling procedure for the current study 
included a three-stage cluster sampling and has been described in 
detail elsewhere.[8] The prespecified age and gender quotas included 
disproportionate sampling across age groups to ensure at least 50 
men and women in each gender category. Among other criteria, 
individuals on tuberculosis or antiretroviral therapy or who had 
received cancer treatment within the past year were excluded. 
Additionally, participants with a self-reported history of ischaemic 
heart disease (IHD) or stroke were excluded for this analysis.
Data collection
Data collected by administered questionnaires included socio-
demographic characteristics, medical history and self-reported 
tobacco use (World Health Organization (WHO) STEP-wise 
surveillance questionnaire).[9] Assets defining wealth were recorded 
and included ownership of consumer items such as a radio, television, 
telephone, refrigerator, personal computer, washing machine, motor 
vehicle, bicycle and electricity, and the source of drinking water and 
toilet facilities.
Height and weight were measured using standardised techniques. 
Three BP measurements were taken at 2-minute intervals and the 
average of the second and third measurements was used in the 
analyses.
Blood samples for lipid and glucose estimations were drawn 
following an overnight fast of 10 hours. A standard oral glucose 
tolerance test was then administered and blood samples taken 120 
minutes later.[10] Blood samples were kept on ice and transported to 
the laboratory within 6 hours to be centrifuged, aliquoted and stored 
at –80° until the assays were performed.
Definitions
Diabetes was diagnosed according to the 1998 WHO criteria,[10] 
the use of hypoglycaemic agents or the subject having being told 
they were diabetic by a doctor/nurse. Hypertension was defined 
as BP  ≥140/90 mmHg or using antihypertensive agents. BMI was 
computed as kg/m2. Smoking status was defined as currently smoking 
daily or occasionally.
The absolute risk of having a CVD event, defined as IHD, stroke, 
transient ischaemic attack or heart failure, within 10 years was 
calculated using the Framingham[11] and NHANES I equations.[12] A 
score ≥20% was considered to indicate high risk and 10 - 19.99% to 
indicate moderate risk.
Statistical analysis
Data analyses were done using STATA 12. Descriptive statistics, 
including crude prevalence, were calculated using the weights based 
on the sample design and adjusted for the realised sample. A principal 
component analysis of the pooled data, based on the assets that 
defined wealth, was used to develop an asset index[13] and categories 
of relative wealth were created using tertiles. The first component 
of the principal component analysis placed the highest loading on 
having a toilet and a tap inside the house and explained 31.0% of the 
variation. The second component seemed to measure the ownership 
of luxury items such as a car and a personal computer and explained 
12.2% of the variation. All variables, except bicycle and telephone, 
had approximately equal loadings.
The equations for calculating the 10-year risk of developing a CVD 
event are gender-specific and include the variables of age, diabetes 
status, smoking status, treated and untreated systolic BP, TC and HDL 
cholesterol levels for the laboratory-based equations. BMI replaced 
lipids in the non-laboratory-based equations.[11,12] Concordance 
correlation coefficients determined the correlations of the mean 
scores calculated by the laboratory-based equations with the two 
non-laboratory based equations. The McNemar test compared the 
frequencies of estimated high risk calculated using the laboratory-
based equations with the two non-laboratory based equations.
The univariate analyses are presented as mean or percentage 
values with 95% confidence intervals (CIs). The unadjusted 
survey-based odds ratio (OR) and 95% CI for the associations of 
the sociodemographic variables with total CVD risk ≥20% were 
calculated. On account of the high level of correlation between the 
risk scores, only the associations for the Framingham laboratory-
based CVD risk scores are presented in men and women. Survey 
multiple logistic regression analyses determined the independent 
associations of the sociodemographic variables with estimated total 
CVD risk ≥20%. The same sociodemographic variables were inclu-
ded in the unadjusted and adjusted analyses. p-values are presented 
for the adjusted analyses.
The University of Cape Town’s Research and Ethics Committee 
approved the study. All participants signed informed consent.
Results
The realised study sample comprised 1 099 participants, 1 025 of 
whom (369 men and 656 women) were included in this analysis. 
Seventy-four participants with a self-reported history of IHD or 
stroke were excluded. The overall response rate was 86%, the 
non-responders, i.e. the selected people who the study team were 
unsuccessful in contacting, totalling 187 (79 men).
The overall mean 10-year risk for a CVD event estimated using 
the laboratory-based scores was low at 7.1% and significantly 
higher in men than in women (9.0% v. 5.4%; p<0.001) (Table 1). 
The non-laboratory-based mean scores were comparable to these 
laboratory-based estimates (Table 1 and Fig. 1). The concordance 
correlations between the Framingham laboratory and non-laboratory 
risk scores were very high at 0.936 for men and 0.924 for women. The 
concordance correlations between the Framingham laboratory-based 
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and NHANES I risk scores were 0.950 and 
0.786 in men and women, respectively.
The prevalence of estimated high 
total CVD risk (≥20%) according to the 
laboratory-based scores was 13.0% in men 
and 6.1% in women (p<0.001) (Table 1). 
In men, the frequencies of estimated high 
risk were significantly different between 
the laboratory-based and the Framingham 
non-laboratory-based scores (p<0.001) but 
were similar between the former and the 
NHANES I non-laboratory scores (p=0.695). 
Taking the laboratory-based scores as the 
gold standard, the sensitivity was 97.0% 
and 79.1%, respectively, and the specificity 
92.7% and 96.0%, respectively. In women, 
the frequencies of estimated high risk were 
significantly different for both comparisons 
(p<0.001). The sensitivity of 98.2% and 
100%, respectively, was very high. The 
specificity for the comparison of estimated 
high risk between the two Framingham 
equations was 96.7% and that between the 
laboratory-based and the NHANES I non-
laboratory scores 89.0%.
The prevalences of the individual 
CVD risk factors were similar in men 
and women for hypertension (p=0.985), 
diabetes (p=0.071) and HDL cholesterol:TC 
<20% (p=0.170) (Fig. 2). Men and women 
differed in smoking prevalence, which was 
significantly higher in men than in women 
(58.4% v. 9.8%; p<0.001). Overweight and 
obesity was significantly higher in women 
(82.0%) than in men (29.2%) (p<0.001).
As shown in Table 2, the adjusted odds for 
estimated high CVD risk by the Framingham 
laboratory-based scores were significantly 
associated with ≤7 years of education (p<0.001) 
and unemployment (p=0.021) in men. The 
significant adjusted odds for estimated high 
CVD risk by the laboratory-based scores in 
women were ≤7 years of education (p<0.001), 
better-quality housing (p=0.044) and being 
in the poorest wealth tertile (p=0.013). The 
work category with pensioners was associated 
with high CVD risk for both men and women 
because of the link with age, which is a function 
of the risk equation.
In the Framingham non-laboratory-based 
logistic models, com pared with the lab-
oratory-based analyses, there were no 
changes in the direction or significance of 
the variables except for housing, which was 
no longer significant in women (p=0.231). 
In the NHANES I logistic models, unlike 
the Framingham laboratory-based analyses, 
better housing (p=0.044) was associated with 
an estimated high CVD risk in men, while 
Table 1. Total CVD risk estimates using laboratory- and non-laboratory-based equations in men and women
Men (N=369) Women (N=656) Total (N=1 025)
n % 95% CI n % 95% CI n % 95% CI
Framingham CVD risk using lipid profiles
Mean 9.0 7.7 - 10.3 5.4 4.7 - 6.1 7.1 6.4 - 7.9
Moderate risk (10 - 19.99%) 57 12.2 9.2 - 16.0 71 8.3 6.3 - 10.9 128 10.2 8.3 - 12.4
High risk (≥20%)* 67 13.0 9.9 - 17.0 55 6.1 4.6 - 8.0 122 9.4 7.6 - 11.6
Framingham CVD risk using BMI
Mean 11.1 9.6 - 12.6 6.8 5.9 - 7.7 8.8 7.9 - 9.7
Moderate risk (10 - 19.99%) 71 16.2 12.6 - 20.7 83 10.3 8.2 - 12.8 154 13.1 11.0 - 15.5
High risk (≥20%)* 87 17.4 13.8 - 21.8 74 8.4 6.4 - 10.9 161 12.7 10.6 - 15.2
CVD risk using BMI (NHANES I)
Mean 9.0 7.6 - 10.3 8.7 7.6 - 9.8 8.8 7.9 - 9.8
Moderate risk (10 - 19.99%) 64 14.5 10.9 - 19.0 84 10.1 8.0 - 12.7 148 12.2 10.1 - 14.6
High risk (≥20%)† 65 12.2 9.3 - 15.7 121 14.0 11.4 - 17.0 186 13.1 11.1 - 15.5
CVD = cardiovascular disease; CI = confidence interval; BMI = body mass index; NHANES = National Health and Nutrition Examination Survey.
Non-laboratory CVD risk scores used BMI instead of lipids. Men compared with women: *p<0.001; †p=0.390.
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Fig. 1. Scatterplots of the Framingham laboratory-based total CVD risk scores with the Framingham 
and NHANES non-laboratory-based CVD risk scores (CVD = cardiovascular disease; NHANES = 
National Health and Nutrition Examination Survey).
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in women housing (p=0.133) and wealth 
(p=0.094) were no longer significant.
Discussion
The CRIBSA study, which is among the first 
to determine the 10-year risk of developing 
a CVD event in an urban African population 
in SA, found a modest prevalence of high 
risk (≥20%) in men and a low to moderate 
prevalence in women. This suggests that 
for cost-effective management, a relatively 
smaller proportion of participants require 
treatment compared with those with 
prevalent individual risk factors. For example, 
while only 13.0% of men and 6.1% of women 
would require interventions according to 
the Framingham laboratory-based high-risk 
estimates, hypertension prevalence was high 
at 35%. This is especially relevant in view of 
the potential burden that may be imposed 
on healthcare services if all individuals with 
only high BP were treated with medication. 
Basing treatment decisions on a total CVD 
risk assessment approach enables individuals 
who would benefit the most from treatment 
to be identified and also results in optimal 
and cost-effective management, as shown 
by Gaziano et al.[14] in an analysis of the SA 
hypertension guidelines.
The data confirm that the use of non-
laboratory scores in clinical practice may be 
a feasible alternative in our setting. There 
was a high correlation between the mean 
laboratory-based and non-laboratory-
based scores, and a high proportion of 
participants identified as at high risk on 
the laboratory-based estimates were also 
identified by the non-laboratory estimates. 
Gaziano et al.[7] also reported high 
correlations between laboratory- and non-
laboratory-based scores in SA populations. 
Eliminating the need for costly laboratory 
measurements will enhance accessibility 
and utility of the total CVD risk assessment 
tool[4] and is particularly relevant in low-
resource settings such as SA that face a high 
burden of multiple diseases.
Estimated high CVD risk by Framingham 
laboratory- and non-laboratory-based scores 
was found to be significantly related to 
unemployment in men, poverty in women 
and lower education levels in both. These 
are vulnerable groups that are likely to be 
less aware of the risks of CVD and may have 
difficulty in accessing healthcare because 
of financial constraints. There is therefore 
a pressing need to increase awareness of 
CVD among these individuals. Additionally, 
they should be targeted for screening and 
prevention of CVD and its risk factors, and 
their access to healthcare, if compromised, 
should be facilitated.
In view of the association of high CVD 
risk with poverty or lower socioeconomic 
status as defined by education level and 
asset index or wealth tertiles, the relation 
between better-quality housing and 
estimated high risk by the Framingham 
laboratory-based scores in women and the 
NHANES I scores in men was unexpected. 
That wealth, education and housing quality 
may not be well correlated possibly accounts 
for these findings, underscoring the fact that 
socioeconomic dynamics are complex and 
further research in this area is needed.
Despite the high prevalence of CVD risk 
factors in both men and women, the two-fold 
greater predicted high risk of Framingham-
based CVD in men compared with women 
is a function of the equations, which allocate 
greater weight to men. In women, while 
high scores identify those at high risk, 
lower scores do not sufficiently ensure 
that individual women are at low risk. 
It is difficult for women aged <75  years, 
even with several markedly eleva ted risk 
factors, to be classified as at high risk.[15] 
Factors beyond the risk scores therefore 
need to be considered when determining 
therapy in women. These models do 
not incorporate all CVD risk factors, 
particularly physical activity and stress. 
They also do not consider the duration 
of exposure to a risk factor, or include 
relevant family history.[15] In addition, for 
CVD risk management in women, medical 
and lifestyle history, markers of preclinical 
disease and other conditions need to be 
considered when determining the intensity 
of preventive therapy. Recommendations 
also include a lower cut-point for defining 
high risk in women as ≥10% 10-year risk 
for all CVD compared with the traditionally 
≥20% 10-year risk estimate utilised.[15] The 
prevalence of high risk in women would 
then be 14.4%, 18.7% and 24.1% by the 
laboratory-based and non-laboratory-
based Framingham and NHANES 1 scores, 
respectively.
Nevertheless, while there are some 
recognised limitations, 10-year risk esti-
mations represent an improvement over 
clinical judgement alone for appropriate 
risk stratification. Considering that a 
systematic approach to total CVD risk 
estimation seems to result in better risk 
factor control,[4] the weaknesses of the CVD 
risk prediction models should not defer the 
control of the major risk factors through this 
cost-effective approach.[2] Total CVD risk 
asse ssment is likely to remain an important 
therapeutic component for individuals and 
populations.
Study limitations
Limitations of the study included the low 
sample realisation in men (64%), which 
necessitated higher sampling weights and a 
loss of precision. The application in this study 
of risk estimation tools developed primarily 
in populations of European origin in wealthy 
regions with different incidences of CVD 
events to our population is another limitation.
Conclusion
Despite the high prevalence of many 
individual CVD risk factors, the estimates 
of a ≥20% 10-year risk for a CVD event in 
the black population of Cape Town were 
moderate in men and low to moderate in 
women, depending on the equation used. 
This implies that for optimal cost-effective 
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Fig. 2. Prevalence of cardiovascular disease risk score components presented according to gender. 
(Hypertension = blood pressure ≥140/90 mmHg or on hypertension treatment; diabetes = raised 
fasting glucose ≥7.0 mmol/l, 2-hour glucose ≥11.1 mmol/l or known diabetes; HDLC = high-density 
lipoprotein cholesterol; TC = total cholesterol; BMI = body mass index.)
RESEARCH
695       October 2014, Vol. 103, No. 10
management of CVD in this 
population, fewer individuals 
require medical intervention 
compared with those with 
raised single risk factors. The 
comparability of the Framingham 
laboratory- and non-laboratory-
based CVD risk estimates 
illustrates the utility of the latter 
in this resource-limited setting 
and could further optimise cost-
effective strategies. In view of 
the fact that in this study high 
CVD risk was associated with 
unemployed men, the poorest 
women and less-educated adults, 
CVD management needs to target 
these vulnerable groups. Future 
research will be required to 
determine whether the total CVD 
risk approach results in improved 
health outcomes and benefits for 
the healthcare system in SA.
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